Compare DLX & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLX | KOD |
|---|---|---|
| Founded | 1915 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.6M | 795.5M |
| IPO Year | N/A | 2018 |
| Metric | DLX | KOD |
|---|---|---|
| Price | $22.22 | $23.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $23.00 | $22.67 |
| AVG Volume (30 Days) | 277.4K | ★ 710.5K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | ★ 47.66 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $2,118,526,000.00 | N/A |
| Revenue This Year | $0.58 | N/A |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | $12.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.61 | $1.92 |
| 52 Week High | $24.30 | $26.21 |
| Indicator | DLX | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 61.28 |
| Support Level | $20.80 | $21.24 |
| Resistance Level | $21.08 | $26.21 |
| Average True Range (ATR) | 0.57 | 1.68 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 93.33 | 64.75 |
Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.